Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cannabidiol in acute early-stage schizophrenia
NCT02088060Phase 2Terminated
- Sponsor
- Central Institute of Mental Health
- Start
- Dec 2015
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of cannabidiol in schizophrenia, sponsored by Central Institute of Mental Health. Started Dec 2015; status: terminated.
02
Drugs
cannabidiol
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT02088060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02088060.